25 completed, 10 unknown, 5 withdrawn, 2 terminated. 12 Phase 2, 11 Not applicable, 2 Phase 4, 1 Early Phase 1, 1 Phase 1.
Follow SARS-CoV-2 Acute Respiratory Disease: new trials by email Literature Review of SARS-CoV-2 Acute Respiratory Disease trials Research Report on SARS-CoV-2 Acute Respiratory Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Povidone Iodine Nasal Application to Prevent Intraoperative Spread of SARS-CoV-2 Povidone Iodine 5% Soln,Top,Kit - SARS-CoV-2 Acute Respiratory Disease | Phase 4 | Withdrawn | University of Iowa | 2024-07-03 | 2023-11-18 | |
| NAC for Attenuation of COVID-19 Symptomatology N-acetylcysteine, Placebo - Covid19, COVID-19 Pneumonia | Phase 2 | Unknown | Cambridge Health Alliance | 200 | 2024-03-31 | 2023-08-07 |
| Clinical Evaluation of the NeuMoDx SARS-CoV-2 Assay (COVID-19) NeuMoDx SARS-CoV-2 Assay - SARS-CoV-2 Acute Respiratory Disease | Terminated | QIAGEN Gaithersburg, Inc | 503 | 2024-02-06 | 2025-03-18 | |
| Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1) Famotidine, Celecoxib, Placebo - 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection | Phase 2 | Withdrawn | Leidos Life Sciences | 2023-02-07 | 2023-10-10 | |
| SARS-COV-2 Screening in Dialysis Facilities Offering SARS-CoV-2 test - End-stage Renal Disease, SARS-CoV-2 Acute Respiratory Disease | Not applicable | Completed | Stanford University | 2389 | 2023-02-06 | 2024-10-30 |
| Study of the Evolution of Olfactory Disorders in Patients With Persistent Loss of Smell Following COVID-19 Clinical examination, Blood collection, Olfactory evoked potentials - SARS-CoV-2 Acute Respiratory Disease | Not applicable | Completed | Institut Pasteur | 30 | 2022-06-20 | 2025-05-14 |
| Efficacy and Safety of Nasal Spray Solution Containing Human IgG1 Anti-COVID-19 Antibody Cocktail Human IgG1 anti-SARS-CoV-2 antibody cocktail, Placebo - SARS CoV 2 Infection, SARS-CoV-2 Acute Respiratory Disease | Not applicable | Completed | Chulalongkorn University | 50 | 2022-04-20 | 2022-07-07 |
| Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19. COVID-19 Vaccine HIPRA 40 ug/dose, Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injection - COVID-19, SARS-CoV-2 Acute Respiratory Disease | Phase 2 | Completed | Hipra Scientific, S.L.U | 26 | 2022-03-25 | 2023-03-01 |
| Safety, Tolerability and Immunogenicity of Gam-COVID-Vac Vaccine in a Nasal Spray Gam-COVID-Vac, Placebo - COVID-19, SARS-CoV-2 Acute Respiratory Disease | Phase 1 / Phase 2 | Unknown | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 400 | 2022-03-08 | 2022-03-08 |
| SOLIDARITY Finland Plus Long-COVID Imatinib, Infliximab - Covid19, Coronavirus Disease 2019 | Phase 4 | Unknown | Clinical Urology and Epidemiology Working Group | 400 | 2022-02-06 | 2022-05-03 |
| A Phase III Trial to Assess the Safety and Immunogenicity of a HIPRA's Candidate Booster Vaccination Against COVID-19. COVID-19 Vaccine 40 ug/dose - COVID-19, SARS-CoV-2 Acute Respiratory Disease | Phase 3 | Completed | Hipra Scientific, S.L.U | 2646 | 2022-02-03 | 2023-03-15 |
| Epileptic Seizure in Epilepsy Patients After SARS-CoV-2 Vaccination inactive SARS-Cov-2 vaccine - Epileptic Seizures Related to Drugs, SARS-CoV-2 Acute Respiratory Disease | Completed | Xijing Hospital | 240 | 2022-01-01 | 2022-04-22 | |
| Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients Famotidine, Celecoxib, Placebo - 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection | Phase 2 | Terminated | Leidos Life Sciences | 4 | 2021-12-29 | 2024-07-09 |
| LEAP-CT for Treatment of COVID-19 Patients (Master Protocol) Famotidine, Celecoxib, Placebo - 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection | Phase 2 | Completed | Leidos Life Sciences | 4 | 2021-12-29 | 2025-12-16 |
| Photodynamic Therapy for COVID-19 Prevention Nasal Photodisinfection, Sham Comparator: Control - COVID-19 Respiratory Infection, SARS-CoV-2 Acute Respiratory Disease | Not applicable | Completed | Ondine Biomedical Inc. | 100 | 2021-12-20 | 2022-08-12 |
| Evaluation of the Post-vaccination Immune Response to COVID-19 in the New Caledonian Population Blood sample collection, Questionnaires - SARS-CoV-2 Acute Respiratory Disease | Not applicable | Completed | Institut Pasteur | 680 | 2021-12-01 | 2022-11-09 |
| Does a Technology Enabled Multi-disciplinary Team-based Care Model for the Management of Long COVID and Other Fatiguing Illnesses Improve Clinical Care of Patients and Represent a Sustainable Approach Within a Federally Qualified Health Center? Extension for Community Healthcare Outcomes - SARS-CoV-2 Acute Respiratory Disease, Myalgic Encephalomyelitis | Not applicable | Active not recruiting | Family Health Centers of San Diego | 20 | 2021-11-30 | 2025-08-06 |
| SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations BMS-986414, BMS-986413 - SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease | Phase 2 | Withdrawn | Imperial College Healthcare NHS Trust | 2021-11-29 | 2023-04-24 | |
| Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration. COVID-19 Vaccine HIPRA, Cominarty (Pfizer-BioNtech) - COVID-19, SARS-CoV-2 Acute Respiratory Disease | Phase 2 | Completed | Hipra Scientific, S.L.U | 887 | 2021-11-16 | 2026-03-11 |
| Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2) COVID-19 Vaccine HIPRA, Cominarty (Pfizer-BioNtech) - COVID-19, SARS-CoV-2 Acute Respiratory Disease | Phase 2 | Completed | Hipra Scientific, S.L.U | 629 | 2021-11-11 | 2024-02-26 |
Showing 20 of 43. Sign in to see all of them.
COVID-19 (27) · Coronavirus Infections (4) · Disease (2) · Hypoxia (2) · Post-Acute COVID-19 Syndrome (2) · Respiratory Distress Syndrome (2) · Severe Acute Respiratory Syndrome (2) · Cytokine Release Syndrome (1) · Fatigue Syndrome, Chronic (1) · Inflammation (1) · Kidney Failure, Chronic (1) · Leukemia (1) · Lung Neoplasms (1) · Lymphoma (1) · Multiple Organ Failure (1)
Lung Diseases (30) · Respiratory Tract Diseases (30) · Coronaviridae Infections (29) · Infections (29) · Nidovirales Infections (29) · RNA Virus Infections (29) · Virus Diseases (29) · Pneumonia, Viral (28) · Respiratory Tract Infections (28) · Pneumonia (27) · Coronavirus Infections (25) · Pathological Conditions, Signs and Symptoms (12) · Pathologic Processes (9) · Signs and Symptoms (5) · Chronic Disease (3)
Celecoxib (3) · Famotidine (3) · HIPRA COVID-19 vaccine (3) · BNT162 Vaccine (2) · Acetylcysteine (1) · Basiliximab (1) · Blood Specimen Collection (1) · COVID-19 Vaccines (1) · Chlorpheniramine (1) · Defecation (1) · Diagnostic Imaging (1) · Ferritins (1) · Gam-COVID-Vac vaccine (1) · Imatinib Mesylate (1) · Infliximab (1)
Hipra Scientific, S.L.U (4) · Leidos Life Sciences (3) · Everly Health (2) · Institut Pasteur (2) · Azienda Ospedaliera Universitaria Integrata Verona (1) · BioNTech SE (1) · Butantan Institute (1) · Cambridge Health Alliance (1) · Chulalongkorn University (1) · Clinical Urology and Epidemiology Working Group (1) · Dr. Ferrer BioPharma (1) · Family Health Centers of San Diego (1) · Fort Worth Clinical Sciences Working Group (1) · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation (1) · Groupe Hospitalier de la Rochelle Ré Aunis (1)
United States (10) · Spain (5) · France (4) · Belgium (2) · Brazil (2) · China (2) · Germany (2) · Italy (2) · Turkey (Türkiye) (2) · United Kingdom (2) · Canada (1) · Croatia (1) · Dominican Republic (1) · Finland (1) · Mexico (1)
Brian A Roberts, MS, PMP (2) · Timothy Bauer, PhD (2) · Andy Peniket (1) · Babatunde L Salako, MBBS, FRCP (1) · Christian Ramers, MD (1) · David Chalvet, MD (1) · Dhammika Leshan Wannigama, MD PhD (1) · Evelina Tacconelli, Professor (1) · Gengyao Hu, doctor (1) · Geoff Block, MD (1) · Glenn Chertow, MD (1) · Jean-Claude Lapraz, MD (1)
PMID 37460353, PMID 10793162, PMID 11103187, PMID 11575407, PMID 12651052, PMID 15269312, PMID 16616661, PMID 19934867, PMID 20843245, PMID 21081765, PMID 21177882, PMID 22011836, PMID 22298659, PMID 23545542, PMID 23688302, PMID 24427348, PMID 25593744, PMID 25693014, PMID 27611637, PMID 27626833, PMID 27782948, PMID 28973363, PMID 29791822, PMID 30012832, PMID 31112383, PMID 31123846, PMID 32007145, PMID 32167524, PMID 32291542, PMID 32329799, PMID 32408107, PMID 32728965, PMID 34001215, PMID 34446110, PMID 35320289, PMID 35733873, PMID 3585433, PMID 36378074, PMID 36716763, PMID 36976655, PMID 37131861, PMID 37527039, PMID 37573421, PMID 37654668, PMID 37730833, PMID 39097927, PMID 39298171, PMID 39325828, PMID 39809095, PMID 8042785
U01AI169477 (1)